CN111630049B - 用于制备2-(5-甲氧基异色满-1-基)-4,5-二氢-1h-咪唑及其硫酸氢盐的方法 - Google Patents

用于制备2-(5-甲氧基异色满-1-基)-4,5-二氢-1h-咪唑及其硫酸氢盐的方法 Download PDF

Info

Publication number
CN111630049B
CN111630049B CN201880076883.0A CN201880076883A CN111630049B CN 111630049 B CN111630049 B CN 111630049B CN 201880076883 A CN201880076883 A CN 201880076883A CN 111630049 B CN111630049 B CN 111630049B
Authority
CN
China
Prior art keywords
formula
methoxyisochroman
ethyl
dihydro
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880076883.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111630049A (zh
Inventor
I·莱蒂宁
M·莱斯基宁
M·马克拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Publication of CN111630049A publication Critical patent/CN111630049A/zh
Application granted granted Critical
Publication of CN111630049B publication Critical patent/CN111630049B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Epoxy Resins (AREA)
  • Detergent Compositions (AREA)
CN201880076883.0A 2017-12-01 2018-11-30 用于制备2-(5-甲氧基异色满-1-基)-4,5-二氢-1h-咪唑及其硫酸氢盐的方法 Active CN111630049B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20176085 2017-12-01
FI20176085 2017-12-01
PCT/FI2018/050864 WO2019106238A1 (en) 2017-12-01 2018-11-30 Process for the preparation of 2-(5-methoxyisochroman-1 -yl)-4,5-dihydro-1 h-imidazole and the hydrogensulfate salt thereof

Publications (2)

Publication Number Publication Date
CN111630049A CN111630049A (zh) 2020-09-04
CN111630049B true CN111630049B (zh) 2023-06-20

Family

ID=64746580

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880076883.0A Active CN111630049B (zh) 2017-12-01 2018-11-30 用于制备2-(5-甲氧基异色满-1-基)-4,5-二氢-1h-咪唑及其硫酸氢盐的方法

Country Status (19)

Country Link
US (1) US11352346B2 (enExample)
EP (1) EP3717476B1 (enExample)
JP (1) JP7339946B2 (enExample)
KR (1) KR102718536B1 (enExample)
CN (1) CN111630049B (enExample)
AU (1) AU2018376872B2 (enExample)
BR (1) BR112020010617A2 (enExample)
CA (1) CA3083734A1 (enExample)
DK (1) DK3717476T3 (enExample)
ES (1) ES2927193T3 (enExample)
HR (1) HRP20221247T1 (enExample)
HU (1) HUE059849T2 (enExample)
IL (1) IL274931B2 (enExample)
LT (1) LT3717476T (enExample)
PL (1) PL3717476T3 (enExample)
PT (1) PT3717476T (enExample)
SI (1) SI3717476T1 (enExample)
WO (1) WO2019106238A1 (enExample)
ZA (1) ZA202003981B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021020935A1 (ko) 2019-07-31 2021-02-04 현대자동차주식회사 차량 내부 네트워크에 대한 sdn 기반의 침입 대응 방법 및 이를 이용한 시스템
AU2022236605A1 (en) * 2021-03-19 2023-11-02 Orion Corporation Tasipimidine formulations and use thereof
JP2025502480A (ja) 2022-01-24 2025-01-24 オリオン コーポレーション イソクロマン－イミダゾール構造のアルファ－２ａアドレナリン受容体アゴニストの新規な硫酸塩形
AU2023215667A1 (en) 2022-02-04 2024-09-12 Orion Corporation Novel salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist
JP2025531623A (ja) 2022-09-28 2025-09-22 オリオン コーポレーション タシピミジンおよびｃｙｐ２ｄ６阻害薬の併用療法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104220437A (zh) * 2012-04-02 2014-12-17 奥赖恩公司 新α2肾上腺素受体激动剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410562B1 (en) * 1998-12-18 2002-06-25 Eli Lilly And Company Hypoglycemic imidazoline compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104220437A (zh) * 2012-04-02 2014-12-17 奥赖恩公司 新α2肾上腺素受体激动剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cyclodehydration of N‑(Aminoalkyl)benzamides under Mild Conditions with a Hendrickson Reagent Analogue;Wendy A. Loughlin等;JOC;第78卷;7356-7361 *
One-step conversions of esters to 2-imidazolines benzimidazoles and benzothiazoles by aluminum organic reagents;Gunter Neef等;JOC;第46卷(第46期);2824-2826 *
Synthesis and Synthetic Applications of 1-Aryl-2-alkyl-4,5-dihydro-1H-imidazoles;Ana M. Reverdito等;Synthetic Organic Chemistry;第42卷;2083–2097 *

Also Published As

Publication number Publication date
IL274931B2 (en) 2023-11-01
US20200308152A1 (en) 2020-10-01
RU2020121597A (ru) 2022-01-04
HRP20221247T1 (hr) 2022-12-09
WO2019106238A1 (en) 2019-06-06
BR112020010617A2 (pt) 2020-11-10
IL274931A (en) 2020-07-30
HUE059849T2 (hu) 2023-01-28
AU2018376872A1 (en) 2020-07-16
RU2020121597A3 (enExample) 2022-01-04
CN111630049A (zh) 2020-09-04
DK3717476T3 (da) 2022-09-05
EP3717476A1 (en) 2020-10-07
JP7339946B2 (ja) 2023-09-06
KR20200095519A (ko) 2020-08-10
US11352346B2 (en) 2022-06-07
SI3717476T1 (sl) 2022-10-28
LT3717476T (lt) 2022-09-26
AU2018376872B2 (en) 2023-12-07
IL274931B1 (en) 2023-07-01
JP2021504418A (ja) 2021-02-15
ZA202003981B (en) 2021-07-28
ES2927193T3 (es) 2022-11-03
PL3717476T3 (pl) 2022-11-21
KR102718536B1 (ko) 2024-10-21
PT3717476T (pt) 2022-08-23
CA3083734A1 (en) 2019-06-06
EP3717476B1 (en) 2022-08-03

Similar Documents

Publication Publication Date Title
CN111630049B (zh) 用于制备2-(5-甲氧基异色满-1-基)-4,5-二氢-1h-咪唑及其硫酸氢盐的方法
JP5632279B2 (ja) 塩酸イバブラジンの調製方法及びポリモルフ
CA2954167C (en) Process for the preparation of 4-alkoxy-3-hydroxypicolinic acids
CN105814020B (zh) 用于大规模生产1‑[(2‑溴苯基)磺酰基]‑5‑甲氧基‑3‑[(4‑甲基‑1‑哌嗪基)甲基]‑1h‑吲哚二甲磺酸盐一水合物的方法
HK1226396A1 (en) Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
CN103958467B (zh) 制备6-氯-2,3,4,9-四氢-1h-咔唑-1-甲酰胺及其前体的方法
WO2018187717A1 (en) Continuous flow synthesis of ibuprofen
TWI291956B (en) Improved process
CN116496214B (zh) 一种手性3-(n-甲基-1,2,3,4-四氢异喹啉)丙酸酯苯磺酸盐的制备方法
WO2012090221A1 (en) Novel salts of imatinib
WO2012127483A1 (en) Processes for the preparation of intermediates of n-[2-(7-methoxy-1-naphthyl) ethyl] acetamide
CA2756234A1 (en) Synthesis of 3-{[(2r)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(phenylsulfonyl)ethyl]-1h-indole
CN113336703B (zh) 1,3,4,5-四取代1h-吡唑衍生物的合成
JP2015038053A (ja) ４−（２−メチル−１−イミダゾリル）−２，２−フェニルブタンアミドの製造方法
RU2791469C2 (ru) Способ получения 2-(5-метоксиизохроман-1-ил)-4,5-дигидро-1h-имидазола и его гидросульфата
MXPA03006215A (es) Un proceso mejorado para preparar clorhidrato de ondansetron dihidratado puro.
WO2019167058A1 (en) An improved process for the preparation of propiomazine maleate
JP2001510830A (ja) １，３−ジアザ−スピロ（４，４）ノン−１−エン−４−オン誘導体及び１−シアノ−１−アシルアミノシクロペンタン中間体の調製方法
WO2026085237A1 (en) Process for preparing 2-isopropyl-5-(isoquinolin-3-yl)benzene-1,3-diol
CN117903138A (zh) 一种拉罗替尼的制备方法和其应用
CN107011301B (zh) 一种2-（2-甲氧基苯基）-5-氧代四氢呋喃-3-羧酸的制备方法
WO2024109801A1 (zh) 一种手性吡咯衍生物的制备方法及其中间体
EP1907377A1 (en) A process for the preparation of almotriptan
WO2014049609A2 (en) Novel salts of vilazodone
CN107628983A (zh) 高手性纯度的阿普斯特

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant